Physician profile
Anupama Gowda
NPI 1508947870
$1,921.62
in general payments reported to CMS, 2019-2025
22 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $486 · 2020: $40.67 · 2021: $91.17 · 2022: $288 · 2023: $353 · 2024: $227 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.41 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $284.82 | 2019-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $233.78 | 2025 | Terlivaz, Acthar |
| Astrazeneca Pharmaceuticals LP | $222.56 | 2019-2025 | Farxiga |
| Travere Therapeutics, INC. | $220.39 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $217.99 | 2019-2024 | Velphoro |
| Amgen INC. | $125.58 | 2019-2025 | Krystexxa, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $97.04 | 2021-2022 | |
| Vifor Pharma, INC. | $94.60 | 2019-2024 | Veltassa |
| Novartis Pharmaceuticals Corporation | $88.30 | 2024-2025 | |
| Mallinckrodt Enterprises LLC | $72.55 | 2019 | |
| Aurinia Pharma U.S., INC. | $45.24 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $37.33 | 2022-2025 | Jynarque |
| Baxter Healthcare | $28.35 | 2023 | Renal - Pd |
| Calliditas Therapeutics US INC. | $26.53 | 2022-2023 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $26.50 | 2023 | Ultomiris |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $25.42 | 2022 | |
| Scpharmaceuticals INC. | $18.30 | 2025 | |
| Daiichi Sankyo INC. | $14.82 | 2020 | |
| Glaxosmithkline, LLC. | $14.14 | 2022 | |
| Akebia Therapeutics INC | $13.89 | 2022 | |
| Opko Pharmaceuticals, LLC | $13.49 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anupama Gowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.